Keywords: آلوگلپتین; Alogliptin; Coronary atherosclerosis; Coronary computed tomography angiography (CCTA); Diabetes mellitus; Fractional flow reserve (FFR);
مقالات ISI آلوگلپتین (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آلوگلپتین; Vildagliptin; Drug-induced liver injury; Hypersensitivity; Covalent binding; Nucleophilic trapping agents; ALG; alogliptin; ANG; anagliptin; CRP; C-reactive protein; CYP; cytochrome P450; DILI; drug-induced liver injury; DLST; drug-induced lymphocyte stim
Keywords: آلوگلپتین; Alogliptin; Advanced amplitude modulation; Derivative ratio; Metformin; Mean centering, Ratio difference;
Keywords: آلوگلپتین; Alogliptin; Picric acid; 2,4 Dinitrophenol; Spectrophotometer; Assay;
Comparative study between different simple methods manipulating ratio spectra for the analysis of alogliptin and metformin co-formulated with highly different concentrations
Keywords: آلوگلپتین; Alogliptin; Metformin; Spectrophotometry; Validation; Ratio spectra manipulation;
A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers
Keywords: آلوگلپتین; ALG; alogliptin; AUC0-t and AUC0-â; the areas under the plasma concentration-time curve; Cmax; maximum plasma concentration; DPP-IV; dipeptidyl peptidase; ER; extraction recovery; GIP; glucose-dependent insulinotropic polypeptide; GLP 1; glucagon-
Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis
Keywords: آلوگلپتین; Nonalcoholic steatohepatitis; Hepatic fibrosis; Alogliptin; Pioglitazone; Combination therapy;
Zinc/alogliptin combination attenuates testicular toxicity induced by doxorubicin in rats: Role of oxidative stress, apoptosis and TGF-β1/NF-κB signaling
Keywords: آلوگلپتین; Zinc sulphate; Alogliptin; Doxorubicin; Testis; Rats;
Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial
Keywords: آلوگلپتین; Alogliptin; Cardiovascular disease; Diabetes; Hypoglycemia; Metformin; Sulphonylurea;
Effects of alogliptin on fractional flow reserve evaluated by coronary computed tomography angiography in patients with type 2 diabetes: Rationale and design of the TRACT study
Keywords: آلوگلپتین; Alogliptin; Coronary atherosclerosis; Coronary computed tomography angiography; Dipeptidyl peptidase-4 inhibitor; Fractional flow reserve;
Enhanced LC-MS/MS analysis of alogliptin and pioglitazone in human plasma: Applied to a preliminary pharmacokinetic study
Keywords: آلوگلپتین; Alogliptin; Pioglitazone; Sample preparation; LC-MS/MS; Human volunteers; Preliminary pharmacokinetic study;
Enhanced LC-MS/MS determination of alogliptin and metformin in plasma: Application to a pharmacokinetic study
Keywords: آلوگلپتین; Alogliptin; Metformin; Tandem mass; Pharmacokinetic study; Egyptian African volunteers;
Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice
Keywords: آلوگلپتین; Alogliptin; DPP-4; GLP-1; 5-HT1B receptor agonist; mCPP
Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice
Keywords: آلوگلپتین; Mosapride; 5-HT4 receptor agonist; Alogliptin; DPP-4 inhibitor; GLP-1; Glucose tolerance
Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin
Keywords: آلوگلپتین; DPP-4 inhibitors; Hybrid compound design; Linagliptin; Alogliptin; Diabetes
DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
Keywords: آلوگلپتین; Clinical trial-DPP-4 inhibitor; Alogliptin; Linagliptin; Saxagliptin; Sitagliptin; Vildagliptin; Type 2 diabetes mellitus; ReviewDiabète de type 2; Essai clinique; Inhibiteur de la DPP-4; Alogliptine; Linagliptine; Saxagliptine; Sitagliptine; Vildagliptin
Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice
Keywords: آلوگلپتین; Pioglitazone; Alogliptin; Insulin therapy; MafA; GLP-1 receptor; β-Cell functions;
GLP-1 for type 2 diabetes
Keywords: آلوگلپتین; GLP-1; DPP-4 inhibition; Type 2 diabetes; Exenatide; Liraglutide; Albiglutide; Taspoglutide; Lixisenatide; Sitagliptin; Vildagliptin; Saxagliptin; Alogliptin; Linagliptin
Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways
Keywords: آلوگلپتین; DPP-4; Alogliptin; Inhibition; Vascular; Cardiovascular
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development
Keywords: آلوگلپتین; Exenatide; Sitagliptin; Saxagliptin and liraglutide; Vildagliptin; Insulin inhalation powder; Alogliptin
Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
Keywords: آلوگلپتین; alogliptin; dipeptidyl peptidase-4 (DPP-4) inhibitor; linagliptin; saxagliptin; sitagliptin; vildagliptin
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Keywords: آلوگلپتین; alogliptin; DPP-4 inhibitors; exenatide; GLP-1 receptor agonists; incretin therapies; liraglutide; saxagliptin; sitagliptin; type 2 diabetes; vildagliptin;
Treatment of elderly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors
Keywords: آلوگلپتین; alogliptin; cardiovascular; hypoglycemia; obesity; saxagliptin; sitagliptin; vildagliptin;
A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure
Keywords: آلوگلپتین; Alogliptin; Type 2 diabetes; Glucagon-like peptide-1; Dipeptidyl peptidase inhibitor-4; Sulfonylurea; N-STZ-1.5 rat; SU secondary failure
The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice
Keywords: آلوگلپتین; Type 2 diabetes mellitus; Alogliptin; Pioglitazone; Dipeptidyl peptidase-4; Glucagon-like peptide-1; ob/ob mice
Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice
Keywords: آلوگلپتین; Type 2 diabetes mellitus; Alogliptin; Dipeptidyl peptidase-4; Incretin; Glucagon-like peptide-1; Glucose-dependent insulinotropic polypeptide; Beta-cell; ob/ob mice
Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys
Keywords: آلوگلپتین; Type 2 diabetes mellitus; Alogliptin; Dipeptidyl peptidase-4; Incretin; Glucagon-like peptide-1